Renova Therapeutics welcomes new board member, raises $7.52 million in Series C financing round

Nov. 18, 2014

San Diego, CA – Renova Therapeutics, a biopharmaceutical company developing gene therapy treatments for congestive heart failure and other chronic diseases, announced that Daniel M. Bradbury joined its board of directors. The company also completed its third round of funding, raising $7.52 million.

Mr. Bradbury is a life sciences executive with more than 30 years of experience in creating transformative business strategies, bringing novel medicines to market and maximizing shareholder value. He is Managing Member of BioBrit, LLC, a Life Sciences Consulting and Investment Firm, and the former President and Chief Executive Officer of Amylin Pharmaceuticals, a biopharmaceutical company focused on metabolic diseases.

“I am excited to join the Renova Therapeutics board,” said Mr. Bradbury. “The company’s gene therapy work is transformational, and their potential for success is great. Renova is poised to help millions of people suffering from congestive heart failure by positively impacting patient outcomes.”

Mr. Bradbury was CEO of Amylin, which was listed on the Nasdaq 100, from March 2007 until Bristol-Myers Squibb acquired the company for $7 billion in August 2012. During Mr. Bradbury’s 18 years at the company, Amylin launched the first once-a-week diabetes therapy and three other first-in-class medicines.

Mr. Bradbury received a Bachelor of Pharmacy from Nottingham University and a Diploma in Management Studies from Harrow and Ealing Colleges of Higher Education in the United Kingdom. He joins the following directors of the Renova Therapeutics board:

• Jack W. Reich, Ph.D., CEO and Co-founder of Renova Therapeutics
• Roy Cosan, President of Renova Therapeutics
• Kirk Hammond, MD, Professor of Medicine, University of California, San Diego, and Co-founder of Renova Therapeutics
• Craig Andrews, COO, Co-founder and Secretary of Renova Therapeutics
• Andy Noorda, Managing Member of The Canopy Group
• Michael Torres, CEO of Adelante Capital Management

Company now funded through 2016

Renova Therapeutics completed its third round of funding on Sept. 30, 2014, raising $7.52 million through a Series C Preferred Stock financing round. Investments in the company have come primarily from high net-worth individuals. The company is funded through 2016.

---